CSM 583 CAPSTONE ADA Compliance: Easy Steps to Get Started with Accessibility By Jeff Statham.
WRLFMD Global update · Begoña Valdazo-González, Britta Wood, Barsha Thapa, Bob Statham, Trish...
Transcript of WRLFMD Global update · Begoña Valdazo-González, Britta Wood, Barsha Thapa, Bob Statham, Trish...
WRLFMD Global update
Donald King
WRLFMD Team: Valerie Mioulet, Nick Knowles, Ginette Wisden, Bryony Armson,
Pip Hamblin, Kasia Bachanek-Bankowska, Kelly Adams, Jemma Wadsworth,
Begoña Valdazo-González, Britta Wood, Barsha Thapa, Bob Statham,
Trish Ryder, Sarah Belgrave
Nigel Ferris Retirement
~35 years
Geoff Hutchings Retirement
40 years
Jef Hammond Director
Elizabeth Macarthur Agricultural Institute
Australia
5 years +
Yanmin Li Head of Vaccine Research
Boehringer-Ingelheim
Shanghai, China
10 years
Recent staff changes at WRLFMD
Preparation for a potential FMD outbreak • Monitoring of risks
• Early warning
• Validation and testing of systems
Global surveillance • Emergence of new viral lineages
• Patterns of virus movement
• Performance of vaccines
Role of WRLFMD
EuFMD strategic
objectives
1
2
3
4
5
• October 2012 – date: 360 samples
• 199 Isolates
• Represent 5 FMDV serotypes:
• No serotype C since 2004
Recent submissions to WRLFMD
O A
Asia 1
SAT 1 SAT 2
Sri Lanka
Bhutan
Hong Kong SAR
PAT
Viral sequences
Clinical samples
Global sampling Countries sending samples to WRLFMD
October 2012 - October 2013
Reports for these samples can be found at www.wrlfmd.org
Enhanced surveillance through the OIE/FAO FMD Laboratory Network
• Approximately 1800 samples tested during 2012
• Report published on an annual basis
• Network meeting in Bangkok (12-14th November)
WRLFMD: Pirbright, UK
RRLSEA: Pakchong, Thailand
LVRI: Lanzhou, China
FGI ARRIAH: Vladimir, Russia
PDFMD: Mukteswar, India
RRLSSA: Gabarone, Botswana
FMD-Laboratory: Embakasi, Kenya
PANAFTOSA: Rio de Janeiro, Brazil
SENASA: Argentina
ARC-OVI: Onderstepoort, RSA
PIADC: Plum Island, USA
CODA-CERVA-VAR: Belgium
Vaccine matching training course – Sept 2013
FMD diagnostics training course – April 2013
Harmonisation of laboratory capabilities: Training and proficiency testing
• Annual training course for laboratory diagnostics
• Training course for vaccine matching
• WRLFMD mission to Balkan States
• Annual proficiency testing scheme
• Aims to harmonise the performance of laboratory tests
• Important component of quality assurance schemes
• 2013 exercise (4 panels):
• 80 invited laboratories
• 46 shipments dispatched
Conjectured Status of FMD
Intermediate, sporadic
Endemic
Free
Free. Virus present in game parks
Free with vaccination
Countries with multiples zones:
FMD-free, free with vaccination or not free
2010-2013: Changing patterns and threats
SAT 2
North Africa
Asia 1
The Middle East
Multiple
East Asia
Changing global patterns: SAT 2 in North Africa
Cameroon 2005
SAT2/LIB/40/2012
SAT2/LIB/41/2012
SAT2/LIB/39/2012
SAT2/SUD/1/2007 (GU566071)
SAT2/NIG/2/2007
SAT2/NIG/5/2008
SAT2/NIG/6/2008
SAT2/NIG/7/2008
SAT2/NIG/4/2008
SAT2/NIG/1/2008
SAT2/NIG/2/2008
SAT2/NIG/3/2008
SAT2/NIG/8/2008
SAT2/LIB/1/2003
SAT2/LIB/7/2003
SAT2/NGR/15/2005
SAT2/SEN/27/2009
SAT2/EGY/2/2012
SAT2/SAU/6/2000 (AF367135)
SAT2/CAR/P12/2000 (VDI 44/1)(HM211082)
SAT2/ERI/12/98 (AF367126)
SAT2/ERI/1/98 (AY343933)
SAT2/ERI/4/98 (AY343934)
SAT2/EGY/9/2012
SAT2/EGY/11/2012
SAT2/EGY/13/2012
SAT2/EGY/6/2012
SAT2/EGY/10/2012
SAT2/EGY/14/2012
SAT2/EGY/15/2012
SAT2/EGY/3/2012
SAT2/EGY/4/2012
SAT2/EGY/5/2012
100
100
79
89
97
98
100
93
100
86
100
100
100
0.01
• First FMD cases in Egypt due to serotype SAT 2 since 1950
• Cases associated with high mortality • ~50% particularly in young animals
due to myocarditis
• Sequence data supported at least two introductions of SAT 2 FMDV into Egypt within the SAT 2 topotype VII
• Distinct from other contemporary SAT 2 lineages in the Middle East and North Africa • topotype VII from Libya
• topotype IV from Bahrain
FMD viruses from Southeast Asia are appearing in East and Central Asia
• O/SEA/Mya-98: • Widespread; at least two introductions
from SEA into China, Russia, Mongolia, North and South Korea, Japan
• A/ASIA/Sea-97: • Introduction from SEA into China and
South Korea, Mongolia (west) and Kazakhstan (2013)
• O/ME-SA/PanAsia: • Introduction from SEA into China and
Kazakhstan (2010)
• What is driving these changing patterns?
MYA/5/2009
46
13
495
MAY/7/2007
82
107
24
3
TAI/22/200976
RUS/Aug 2010
JPN/1/2010
BY/CHA/2010
3325
25
57
GZ/CHA/2010
31
CHN/Mya98/33-P
48
1
HKN/15/2010
232
25
2
56
SKR/5/2010
DKR/31/2011
23
14
35
30 [98]
21
34
HKN/20/2010
GSLX/2010
27
22
MOG/7/2010
MOG/C-10/2010
25
37
SKR/4/2010
2
1
RUS/Jul 2010
Knowles et al., 2012
Valdazo-Gonzalez et al., 2013
Changing global patterns: East and Central Asia
TCS: Full genome
1000 km
600 mi
© Daniel Dalet / d-maps.com
152
292
6
32
3
135
2
2
2
Vaccines
A May97 A22 Irq A Iran 05 A Tur 06
Field Viruses
A/MOG/1/2013
A/MOG/5/2013
A/VIT/25/2012
A/VIT/26/2012
A/TAI/13/2012 borderline
A/TAI/16/2012
A/TAI/2/2013
A/TAI/5/2013
A/VIT/5/2013 borderline
A/VIT/6/2013
A/VIT/15/2012
A/VIT/16/2012
Match
No Match
Monitoring vaccine matching A/ASIA/Sea-97 viruses from Southeast and East Asia
Traffic lights
Recent results:
Kazakhstan: FMD Threats (South East Asia)
Spread of two different serotype O lineages and serotype A
• O/ME-SA/PanAsia – Kazakhstan (2010) – also reported in China
• A/ASIA/Sea-97 – Kazakhstan (2013) – also reported in China
and South Korea
• O/SEA/Mya-98 – a number of outbreaks in China (west), Russia,
Mongolia, N&S. Korea, Japan
Kurchum
Urdzhaz
(New) connections between The Middle East and East Asia
Kazakhstan: FMD Threats
Spread of two different serotypes from South Asia/Middle East • O/ME-SA/PanAsia-2 - in Kazakhstan (2010-2012) • A/ASIA/Iran-05 - in Kazakhstan (2012) also recent incursions into
Russia (North Caucasus)
(New) connections between The Middle East and East Asia
Changing global patterns: Spread of new antigenic variants in the Middle East
• Emergence of a new Asia 1 lineage
(Sindh-08) with poor match Asia 1
Shamir (ISR/3/89) • First recognised in Pakistan (2008)
• Natural immunity may be low in
Middle East
• Lineage has now spread westward
into Afghanistan, Iran, Turkey and
Bahrain
• Spread mirrors recent trans-
boundary movements of O/PanAsia
and A/Iran-05
• Can we predict when/where these
events will occur?
Differences (in red) between Asia 1 Shamir
(ISR/3/89) and Asia 1 PAK/29/2009 (Sindh-08)
Vaccines
Asia1 Shamir (normal payload)
Asia1 Shamir
(high payload)
Asia 1 Ind 8/79
Field Viruses
TUR 2/2013
TUR 13/2013
PAK 10/2012
PAK 29/2012
PAK 30/2012
PAK35/2012
PAK 37/2012
PAK 91/2011
PAK 5/2012
AFG 66/2011
AFG 78/2011
IRN 54/2011
IRN 10/2012
Sindh-08 lineage: Lack of protection of existing Asia 1 vaccines
Match
No Match
• Established in 2010
• Important forum for antigen/vaccine banks stakeholders
• Exchange of information/new developments
• Harmonisiation of standards
• Pont of contact with vaccine manufacturers
• EU, QUAD countries, Mexico
• Annual Report 2013
• Current Chair (from 1st October) – Dr Hernando Duque (APHIS, USA)
• Next meeting (teleconference) scheduled within the next 4 weeks
• Opportunities for increased coordination in other areas?
• Diagnostic reserve (commercial NSP/SP assays)
Working together: International FMD Vaccine Strategic Reserves Network
WRLFMD: The future
Pirbright Institute Redevelopment: High Containment Laboratory (DP1)
Building infrastructure will be completed by Q1 2014